Twenty-eight patients undergoing bone marrow transplantation (BMT) were followed-up at weekly intervals from day -10 to discharge from hospital after BMTfor human cytomegalovirus (HCMV) infection using polymerase chain reaction (PCR), slot-blot hybridization, and conventional virus culture. High specificity of the PCR assay applied could be shown by failure to amplify DNA extracted from a wide range of other viruses frequently infecting marrow transplant recipients. The PCR technique allowed us to diagnose viremia and viruria in 20 (83%) of 24 seropositive patients after BMT, whereas culture assays showed 16 (67%) of 24 of these patients to be viruric and 9 (37%) of 24 cases to be viremic. Slot-blot hybridization showed a frequency of viruria and LLOGENEIC BONE MARROW transplantation A (BMT) is frequently complicated by human cytomegalovirus (HCMV) infection in association with severe or even fatal graft-versus-host disease (GVHD).' Although in animals induction and aggravation of acute GVHD by cytomegalovirus has been demonstrated: in clinical studies334 despite serologic evidence' no temporal relationship between HCMV infection and acute GVHD (aGVHD) could be shown. With the use of conventional virologic assays, such as virus culture, HCMV infection cannot usually be diagnosed earlier than 6 to 8 weeks after BMT.6 Serologic tests for the detection of specific IgG or IgM antibodies are also not reliable in these patients because of the applied transfusion therapies or the still-defective humoral antiviral immune responses. For an early prevention and consequent therapy of severe clinical symptoms, as well as for an evaluation of the role of the virus in the pathogenesis of graft rejection or GVHD, faster and more sensitive diagnostic techniques of HCMV infection are required in these patients.
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Recent studies established higher sensitivity of hybridization compared with virus culture techniques for HCMV detection in clinical specimen^.'^' Further improvement in virus detection was achieved by the introduction of the polymerase chain reaction (PCR) allowing highly specific amplification of viral DNA from infected tissues. ' 
Thus, diagnosis of human immunodeficiency virus (HIV) infec-
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section I734 solely to indicate this fact. tion could be established several months before positive reactions in serologic assays.'O In this study, PCR, in association with a radioactive HCMV-DNA detection system, was evaluated for its sensitivity and practical value in the diagnosis of HCMV infection after BMT in comparison with conventional culture tests and slot-blot and in-situ hybridization assays. The main aim of the study was to determine whether application of these techniques applied shortly after BMT might allow detection of the virus earlier than reported up to now in the posttransplant period.
MATERIALS AND METHODS
Patients and clinical specimens. Twenty-eight recipients of an allogeneic BMT were followed-up for HCMV infection by different techniques until discharge from hospital (median: 10 weeks after BMT). Five patients died during in-patient treatment after BMT. Patient characteristics are given in Table 1 . Only four of the patients studied were seronegative for HCMV and received transplants from seronegative donors as well as seronegative blood products. All the patients received oral acyclovir (4 x 400 mddie) and all the seropositive patients additionally HCMV hyperimmune globulin every third week beginning on day -10 until day +lo0 after BMT.
Clinical specimens analyzed are shown in Table 2 . Six percutaneous and postmortem liver biopsy samples and four postmortem lung biopsy specimens obtained from the patients prospectively studied were examined for the presence of HCMV. To increase the number of samples for this analysis another 12 postmortem lung biopsy samples (six from patients with interstitial pneumonia) and 11 liver samples cryoconserved from patients after allogeneic BMT not included in the prospective analysis were studied. All the samples were cryopreserved until used.
Informed consent was obtained from all patients or their parents to use a part of the clinical material obtained for routine diagnostic evaluation in this study. Approval for the study was also obtained from the local ethic committee.
The laboratory HCMV strain AD169, as well as 50 different clinical isolates of HCMV, were used for amplification by PCR. Most of the wild-type HCMV isolates were obtained from organ transplant recipients, others were derived from children with acquired HCMV infection. To control for nonspecific amplification of other viral DNA fragments, lowpassage clinical isolates of varicella-zoster-virus (VZV), herpes simplex virus type I and 11, several strains of adenoviruses, as well Kms strains and control cells. 11,067 bp, immediate early region) cloned in the bacterial vector pACYC 184" was applied. Multiprime labeling of this probe with the use of "P-dCTP to a very high specific activity for slot-blot and with the use of "S-dCrrP for in-situ hybridization was ~s e d . '~. '~ For HCMV-DNA amplification, primer I, identical to position 1767 to 1786, and primer 11, complementary to the sense strand between position 1894 to 1913 of the fourth exon of the immediate early gene of AD169, were synthesized on a Pharmacia Gene Assembler." In addition, a M-mer oligonucleotide homologous to a central region of the amplified region" was also synthesized and used in slot-and Southern blot analysis of the PCR products.
Blood and urine were conventionally inoculated on human embryonic lung fibroblasts maintained according to standard tissue culture techniques. HCMV was identified by the production of characteristic cytopathic effects on human embryonic lung fibroblasts after at least 4 weeks of culture. Monoclonal antibodies (MoAbs) directed against the early and immediate early antigen were additionally applied 48 hours after inoculation of the fibroblasts for detection of viral antigen expression.
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Preparation of target DNA. DNA was extracted from urine (40 mL), blood cells, infected and noninfected fibroblasts, as well as from tissue biopsies after proteinase K digestion using the phenol/ chlorofodisoamylalcohol extraction and precipitation as described.","
Two micrograms of each DNA preparation (200 p,g/mL) or the total amount of DNA extracted from 20 mL urine were spotted onto prewetted nylon membranes (Biotrace; Biotest, Frankfurt, Germany). Prehybridization and hybridization of the membranes were performed as previously r e p~r t e d . '~"~ Autoradiography of the filters was performed on X-Omat AR Kodak films at -80°C for 24 to 96 hours.
Pretreatment of the glass slides, cryostat sectioning of tissues, prehybridization, and hybridization were performed as previously described." Autoradiography was performed with NTB2 nuclear track emulsion (Eastman Kodak) diluted 1:l with 600 mmol/L ammonium acetate. After exposure for 28 days at 4"C, slides were developed and evaluated with a Zeiss interference contrast microscope. For each biopsy, hybridizationpositive cells (25 grains over background) were counted in four sections.
PCR. Amplification of a 147-bp DNA fragment between positions 1767 and 1913 of the fourth exon of the immediate early gene of the HCMV strain AD169 using primer I and I1 has been described before." Briefly, 100 ng of extracted DNA (after two cycles of phenol/chloroform/isoamylalcobol extraction and precipitation) were denatured at 94°C for 5 minutes and specifically amplified in 50 p,L reaction mixture of 10 mmol/L Tris-HC1, pH 9.6, 10 mmol/L MgCl,, 50 mmol/L NaCI, 1 mmol/L deoxyadenosine triphosphate (dATP), 1 mmol/L dCTP, 1 mmol/L deoxyguanosine triphosphate (dGTP), 1 mmoUL dTTP, 10 kg bovine serum albumin (BSA), 0.25 pg of each primer I and 11, as well as of 1 U Taq polymerase (Perkin Elmer-Cetus, Emeryville, CA). Thirty-two cycles, each of which included 3 minutes for annealing and primer extension at 66°C followed by 1 minute of denaturation at 94T, were used.
To minimize the risk of contamination, the PCR technique was physically separated from the laboratory area where DNA extraction and DNA recombinant research was performed. To exclude the presence of polymerase inhibitors and to control the quality of the extracted DNA, a fragment of the human HLA class I gene (4th Slot-blot hybridization.
In-sifu hybridization. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From exon, 129-bp long) was amplified in all samples in parallel (unpublished results). If more than 400 ng DNA could be extracted from the material, analyzed amplification of the class I gene was performed in an extratube with 100 ngof the extracted DNA. If less than 400 ng DNA was precipitated from the material analyzed, the HJA class I gene control was amplified in the same tube (this only applies to some urine samples). Because of the thorough DNA extraction, applied amplification of the control DNA sequence could be demonstrated for all the samples analyzed. Each PCR analysis of clinical samples from patients before and after BMT included titrated cloned pCM5018 and infected fibroblasts as positive, as well as noninfected fibroblasts, and at least four samples of DNA from peripheral blood of sero-and culturenegative normal donors as negative controls, to ascertain standardized conditions and specific amplification in each experiment. Three assays had to be discounted because of false positive negative controls. After thorough exclusion of contamination the tests were repeated and only evaluated when all the negative
" a m controls were negative for viral DNA amplification in the agarose gel as well as after hybridization. Results were considered valid only if consistent in at least two independent experiments. To control for false positive results because of lane carry-over in the Southern blot analysis, the order of the amplification products on the gels was randomly altered in repeated experiments.
Ten-microliter aliqots of each amplification reaction were electrophoretically separated in a 2% agarose gel and either stained directly by ethidium bromide or transferred by vacuum filtration onto nylon membranes (Biotrace; Biotest). After prehybridization (20 mmol/L phosphatebuffered saline [PBS], pH 7.0, 1OX Magic Denhardt's, 7% sodium dodecyl sulfate (SDS), 5X SSC [20X SSC = 3 mol/L NaCI; 0.3 Na-citrate pH 7.01, salmon sperm DNA 100 clg/mL) for 1 hour at 50°C the filters were hybridized for Southern blot analysis with 1 x lo6 cpm/mL of the gamma 3ZP-dATP+znd-labeled internal oligonucleotide16 for 16 hours at 50°C. After two washings, each at 50°C for 1 hour, with 3X SSC, 1OX Magic Denhardt's, 5% SDS in PBS first Analysis of HCMV amplificaiion products. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From and then with 1X SSC, 1% SDS, the filterswere air-dried. Autoradiography of the filters was performed on an X-Omat AR Kodak film at -80°C.
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RESULTS
Sensitivity and specificity of PCR analysis of H C W PCR analysis of the cloned titrated HCMV-DNA fragment pCM5018 showed that 10 fg of homologous HCMV-DNA amplified according to the previously described procedure" was still directly visible after electrophoresis and ethidium bromide staining in a 2% agarose gel (Fig 1A) . After blotting and hybridization with a '*P-end-labeled detection oligonucleotide (Fig 1B and C) , a detection limit of 0.1 fg of amplified homologous HCMV-DNA corresponding to a sensitivity of about 10 virus copies could be achieved after 12 hours of exposure. Similar results were obtained in slot-blot hybridization assays of the amplification products. Reconstitution of the titrated cloned pCM5018 fragment with 1 kg of cellular DNA from noninfected fibroblasts did not reduce this sensitivity. Fifty different clinical isolates of HCMV showed equivalent amplification by PCR. In contrast, no amplified DNA fragments detectable on agarose gel-electrophoresis could be obtained from clinical isolates of other herpes or non-herpes viruses (VZV, herpes simplex virus [HSV] type I and 11, EBV, several strains of adenoviruses). Similarly, control DNA extracted from noninfected fibroblasts gave no amplification signals even after hybridization with the specific detection oligonucleotides. However, fibroblasts inoculated with HCMV strain AD169 for 6 days were shown to be strongly positive by PCR.
Four seronegative patients transplanted from seronegative donors who also received only seronegative blood products were followed-up after BMT for up to 10 weeks. None of the urine and blood samples obtained from these patients before and after BMT was found to be HCMV positive by PCR as shown in Table 2 .
Twenty-four seropositive patients were investigated 10 days before and up to discharge from hospital or death after BMT for HCMV reactivation using the PCR technique in comparison with conventional culture and hybridization assays ( Table 2 ). All 30 blood and 28 urine samples obtained before BMT were found to be negative for HCMV by culture and conventional slot-blot hybridization. However, after PCR amplification, peripheral blood cells of three IgG seropositive patients were shown to contain HCMV-DNA ( Table 2) . Two of these patients had been diagnosed as suffering from a primary or reactivated cultureproven HCMV infection 6 to 8 weeks before the HCMVpositive blood samples were drawn. The other patient had received multiple blood transfusions unscreened for HCMV before BMT. HCMV viremia was no longer demonstrable in these patients during the first 2 weeks after BMT.
Twenty of the 24 seropositive patients analyzed after BMT developed HCMV viremia and viruria 1 to 6 weeks posttransplantation, as shown by PCR amplification ( Fig  1C and 2, Table 3 ). HCMV could be cultured from urine in 16 of these patients and from blood only in nine of the 20 PCR analysis of clinical samples after BMT. 
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5 . + 6 . PCR-positive cases. Slot-blot hybridization without DNA amplification showed the presence of HCMV in urine and blood samples of 12 patients. In nine of these patients, bone marrow cells were also found to harbor HCMV by PCR analysis. PCR analysis always showed HCMV detection in urine and blood before the other techniques showed presence of the virus (Fig 2 and Table 3) . The results of the PCR and culture assay shown on Table 3 are representative for the group of patients with symptomatic (patient A) and asymptomatic infection (patient B). In two of the patients treated with ganciclovir and hyperimmunoglobulin, HCMV elimination from blood and also from other organ tissues could be documented. In eight other patients followed-up after BMT, clearance of the virus from the blood could also be documented by the PCR technique 6 to 18 months after BMT (data not shown). In one patient, the virus was still detectable in the blood 20 months after BMT.
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The most sensitive detection of HCMV in lung and liver specimens of seropositive patients after BMT also could be achieved by the PCR technique when compared with other hybridization and cultural diagnostic assays (Table 4 ). All patients with interstitial pneumonia (N = lo), as well as one patient with obliterative bronchiolitis, were found by the PCR technique to carry HCMV in their lung tissues. Four seropositive patients with HCMV infection of blood or urine documented by culture assays and one seronegative patient were negative for HCMV in lung tissues as shown by all applied diagnostic test systems.
In 13 of 14 seropositive patients (seven included in the prospective analysis) with PCR-positive blood samples, HCMV could also be demonstrated by PCR technique in liver samples obtained postmortem or for diagnostic purposes. Ten of these patients had culture-proven viruria, (Table 5 ). Whereas six patients with symtomatic HCMV infection were viremic and viruric as demonstrated by both techniques, two patients with fatal HCMV disease were only positive in the PCR assay (Table 5 ).
DISCUSSION
In this study the highly sensitive PCR was applied to diagnose HCMV infection after BMT. A high specificity of the assay could be demonstrated by the lack of amplification of the DNA of a wide range of other viruses that can also affect the patient in the early phase following BMT. Additionally, a large number of wild strains of HCMV were shown to give amplification products in the PCR assay applied. Because of the high sensitivity of the method, several precautions, which included pretitration of buffer and enzymes for amplification as well as application of several different standardized negative controls and amplification of very small samples of the highly purified DNA of clinical samples, were performed in each experiment to minimize the risk of false positive results because of minute contaminations.
In the PCR assay 83% of all seropositive patients were found to have HCMV-DNA in the blood and urine after BMT, whereas culture assays showed 67% of these patients to be viruric and 37% to be viremic. Slot-blot hybridization showed a frequency of viruria and viremia in 50% of these cases. The PCR technique, in contrast to virus culture techniques and slot-blot hybridization, for the first time allowed detection of the virus in the very early posttransplant period. In 80% of the PCR-positive patients the virus also could be cultivated at least from the urine in the later posttransplant period. Thus, in the vast majority of patients not only false positive results of the PCR technique were highly unlikely, but also the viral DNA detected appeared to be associated with active viral infection.
Frequently, a more widespread presence of the virus could be shown by PCR technique for patients diagnosed to be only viruric by culture technique. Most striking, all the postmortem lung biopsies obtained from patients with interstitial pneumonia, among them three culture-negative biopsies, were found to contain HCMV as shown by the PCR technique. In the light of these results further studies of lung biopsy specimens of patients with interstitial pneumonia are required to redefine the term idiopathic pneumonia and to determine the role of HCMV in the pathogenesis of interstitial pneumonia.
The early occurrence of the virus in transplant recipients as demonstrated here might also explain immunologic alterations associated with HCMV infection, such as acute and chronic GVHD and graft rejection. In this study, five 
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For personal use only. on October 3, 2017. by guest www.bloodjournal.org From seropositive patients were found to develop HCMV infection before the occurrence of acute GVHD by PCR analysis only. Thus, at least a temporal association between HCMV infection and aGVHD could be shown for some patients analyzed. This result had not been possible applying conventional virus culture technique^.',^ Further studies applying this very sensitive technique will have to evaluate the clinical relevance of the viral DNA detected for the development of HCMV disease as well as for inducing or aggravating immunologic complications following BMT. Because of its high sensitivity, the PCR technique presented might also allow improved evaluation of the different cells and organs affected by latent infection in healthy individuals, and thus help to further exclude blood products or transplants of risk for HCMV transmission.
